Stay updated on LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial
Sign up to get notified when there's something new on the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page.

Latest updates to the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check49 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check63 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.3%
- Check70 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant revision.SummaryDifference1.0%
- Check99 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
Stay in the know with updates to LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page.